Explore expert articles, in-depth analysis and stay informed with the latest in virology from Advanced Virology.
Advanced Virology now offers custom-order Bundibugyo Ebolavirus VLPs designed for assay development, immunology, vaccine research, diagnostics, and countermeasure evaluation.
Every year, preclinical research in the United States wastes an estimated $28 billion on irreproducible studies...
Whether developing vaccines, testing antivirals, or building diagnostic assays, success depends heavily on the fidelity of the virus stocks used during R&D.
In recent years, reverse genetics has emerged as a more precise and powerful alternative to serial passaging, offering a range of advantages in the production of virus stocks.
Utilizing Reporter Viruses in Antiviral Drug Discovery Antiviral drug discovery is a cornerstone of modern infectious disease research. Rapid screening of compound libraries and accurate quantitation of virus replication are...
We’re pleased to announce that Advanced Virology is now live on Scientist.com, providing research organizations with another convenient channel to access our virology products and services.
Since the establishment of virology over a century ago, serial passaging of virus stocks has been used to study viruses and develop products such as vaccines for medical use.
Advanced Virology Inc. is seeking an experienced virologist to support production of high-quality viral products for use in downstream R&D and product manufacturing.
Advanced Virology is proud to share that we have been awarded a $50,000 grant through ACX Grants 2025, a program funded by the ACX community and administered through the nonprofit...
Subscribe to our newsletter for industry insights and research updates.
Subscribe to our newsletter for industry
insights and research updates.